Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database
Biological therapies (BTs) including infliximab (IFX), adalimumab (ADL), secukinumab (SCK) and ustekinumab (UST) are approved in Japan for the treatment of psoriasis. Although the persistence rates and medical...
Source: BMC Dermatology - Category: Dermatology Authors: Rosarin Sruamsiri, Kosuke Iwasaki, Wentao Tang and J örg Mahlich Tags: Research article Source Type: research
More News: Databases & Libraries | Dermatology | Humira | Japan Health | Psoriasis | Remicade | Skin | Stelara | Study